tiprankstipranks
Eli Lilly & Co (GB:0Q1G)
LSE:0Q1G
UK Market
0Q1G
Eli Lilly & Co
RESEARCH TOOLSreports

Eli Lilly & Co (0Q1G) Share Forecast & Price Target

32 Followers
See the Price Targets and Ratings of:

0Q1G Analyst Ratings

Strong Buy
21Ratings
Strong Buy
18 Buy
2 Hold
1 Sell
Based on 21 analysts giving stock ratings to
Eli
Lilly & Co
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0Q1G Stock 12 Month Forecast

Average Price Target

CHF1,110.18
▲(8.84% Upside)
Based on 21 Wall Street analysts offering 12 month price targets for Eli Lilly & Co in the last 3 months. The average price target is CHF1,110.18 with a high forecast of CHF1,294.12 and a low forecast of CHF760.30. The average price target represents a 8.84% change from the last price of CHF1,020.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"454":"CHF454","1295":"CHF1,295","664.25":"CHF664.3","874.5":"CHF874.5","1084.75":"CHF1,084.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1294.1204,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF1.29K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1110.17651025,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF1.11K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":760.295735,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF760.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[454,664.25,874.5,1084.75,1295],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1020,1041.0861846153846,1062.1723692307692,1083.2585538461537,1104.3447384615386,1125.4309230769231,1146.5171076923077,1167.6032923076923,1188.6894769230769,1209.7756615384615,1230.8618461538463,1251.9480307692309,1273.0342153846154,{"y":1294.1204,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1020,1026.9366546346155,1033.8733092692307,1040.8099639038462,1047.7466185384615,1054.683273173077,1061.6199278076924,1068.5565824423077,1075.4932370769232,1082.4298917115386,1089.3665463461539,1096.3032009807694,1103.2398556153846,{"y":1110.17651025,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1020,1000.0227488461538,980.0454976923077,960.0682465384616,940.0909953846154,920.1137442307693,900.1364930769231,880.1592419230769,860.1819907692308,840.2047396153846,820.2274884615385,800.2502373076924,780.2729861538462,{"y":760.295735,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":534.906,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":455.661,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 73,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":455.661,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":456.842,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":456.842,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":456.842,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":458.165,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":712.148,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":677.287,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 90,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":680,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 87,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":680,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 78,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":680,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1020,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF1,294Average Price TargetCHF1,110Lowest Price TargetCHF760.30
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
HSBC Analyst forecast on GB:0Q1G
Rajesh Kumar
HSBC
HSBC
CHF687.5→CHF760.3
Sell
-25.46%
Downside
Reiterated
09/10/26
Eli Lilly price target raised to $940 from $850 at HSBCEli Lilly price target raised to $940 from $850 at HSBC
Barclays Analyst forecast on GB:0Q1G
Emily Field
Barclays
Barclays
CHF1,132.36
Buy
11.02%
Upside
Reiterated
09/08/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (NASDAQ: BNTX) and Eli Lilly & Co (NYSE: LLY)
J.P. Morgan Analyst forecast on GB:0Q1G
Chris Schott
J.P. Morgan
J.P. Morgan
CHF1,132.36
Buy
11.02%
Upside
Reiterated
09/02/26
Eli Lilly Buy Rating Reiterated as Analyst Sees Multi‑Year Growth Upside, Maintains $1,400 December 2026 Price Target
Citi Analyst forecast on GB:0Q1G
Geoff Meacham
Citi
Citi
CHF1,294.12
Buy
26.87%
Upside
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX), Incyte (NASDAQ: INCY) and Eli Lilly & Co (NYSE: LLY)
Jefferies Analyst forecast on GB:0Q1G
Akash Tewari
Jefferies
Jefferies
CHF1,091.91→CHF1,164.71
Buy
14.19%
Upside
Reiterated
09/01/26
Jefferies Sticks to Its Buy Rating for Eli Lilly & Co (LLY)
BMO Capital Analyst forecast on GB:0Q1G
Evan Seigerman
BMO Capital
BMO Capital
CHF1,132.36
Buy
11.02%
Upside
Reiterated
08/31/26
Analysts' Top Healthcare Picks: Eli Lilly & Co (LLY), Novartis (NVS)
Bernstein Analyst forecast on GB:0Q1G
Courtney Breen
Bernstein
Bernstein
CHF1,120.22
Buy
9.83%
Upside
Reiterated
08/31/26
Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON), Eli Lilly & Co (NYSE: LLY) and Rocket Pharmaceuticals (NASDAQ: RCKT)
DBS Analyst forecast on GB:0Q1G
Nico Chen
DBS
DBS
CHF1,253.68
Buy
22.91%
Upside
Reiterated
08/25/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Eli Lilly & Co (NYSE: LLY)
Bank of America Securities Analyst forecast on GB:0Q1G
Jason Gerberry
Bank of America Securities
Bank of America Securities
CHF1,087.06
Buy
6.57%
Upside
Reiterated
08/21/26
Eli Lilly Buy Rating Reiterated on Durable Incretin and Obesity Growth, Price Target Maintained at $1,344
Berenberg Bank Analyst forecast on GB:0Q1G
Kerry Holford
Berenberg Bank
Berenberg Bank
CHF918.02→CHF986.77
Hold
-3.26%
Downside
Reiterated
08/13/26
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY) and Ascendis Pharma (NASDAQ: ASND)
Truist Financial Analyst forecast on GB:0Q1G
Srikripa Devarakonda
Truist Financial
Truist Financial
CHF1,112.94
Buy
9.11%
Upside
Reiterated
08/11/26
Truist Financial Sticks to Their Buy Rating for Eli Lilly & Co (LLY)
Goldman Sachs Analyst forecast on GB:0Q1G
Asad Haider
Goldman Sachs
Goldman Sachs
CHF1,037.72→CHF1,105.66
Buy
8.40%
Upside
Reiterated
08/06/26
Analysts' Top Healthcare Picks: Amgen (AMGN), Eli Lilly & Co (LLY)
Morgan Stanley Analyst forecast on GB:0Q1G
Terence Flynn
Morgan Stanley
Morgan Stanley
CHF1,089.49→CHF1,147.72
Buy
12.52%
Upside
Reiterated
08/06/26
Eli Lilly price target raised to $1,419 from $1,347 at Morgan StanleyEli Lilly price target raised to $1,419 from $1,347 at Morgan Stanley
Scotiabank Analyst forecast on GB:0Q1G
Louise Chen
Scotiabank
Scotiabank
CHF1,051.47
Buy
3.09%
Upside
Reiterated
08/06/26
Scotiabank Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)
Cantor Fitzgerald Analyst forecast on GB:0Q1G
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
CHF1,091.91→CHF1,140.44
Buy
11.81%
Upside
Reiterated
08/06/26
Eli Lilly price target raised to $1,410 from $1,350 at Cantor FitzgeraldEli Lilly price target raised to $1,410 from $1,350 at Cantor Fitzgerald
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
HSBC Analyst forecast on GB:0Q1G
Rajesh Kumar
HSBC
HSBC
CHF687.5→CHF760.3
Sell
-25.46%
Downside
Reiterated
09/10/26
Eli Lilly price target raised to $940 from $850 at HSBCEli Lilly price target raised to $940 from $850 at HSBC
Barclays Analyst forecast on GB:0Q1G
Emily Field
Barclays
Barclays
CHF1,132.36
Buy
11.02%
Upside
Reiterated
09/08/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (NASDAQ: BNTX) and Eli Lilly & Co (NYSE: LLY)
J.P. Morgan Analyst forecast on GB:0Q1G
Chris Schott
J.P. Morgan
J.P. Morgan
CHF1,132.36
Buy
11.02%
Upside
Reiterated
09/02/26
Eli Lilly Buy Rating Reiterated as Analyst Sees Multi‑Year Growth Upside, Maintains $1,400 December 2026 Price Target
Citi Analyst forecast on GB:0Q1G
Geoff Meacham
Citi
Citi
CHF1,294.12
Buy
26.87%
Upside
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX), Incyte (NASDAQ: INCY) and Eli Lilly & Co (NYSE: LLY)
Jefferies Analyst forecast on GB:0Q1G
Akash Tewari
Jefferies
Jefferies
CHF1,091.91→CHF1,164.71
Buy
14.19%
Upside
Reiterated
09/01/26
Jefferies Sticks to Its Buy Rating for Eli Lilly & Co (LLY)
BMO Capital Analyst forecast on GB:0Q1G
Evan Seigerman
BMO Capital
BMO Capital
CHF1,132.36
Buy
11.02%
Upside
Reiterated
08/31/26
Analysts' Top Healthcare Picks: Eli Lilly & Co (LLY), Novartis (NVS)
Bernstein Analyst forecast on GB:0Q1G
Courtney Breen
Bernstein
Bernstein
CHF1,120.22
Buy
9.83%
Upside
Reiterated
08/31/26
Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON), Eli Lilly & Co (NYSE: LLY) and Rocket Pharmaceuticals (NASDAQ: RCKT)
DBS Analyst forecast on GB:0Q1G
Nico Chen
DBS
DBS
CHF1,253.68
Buy
22.91%
Upside
Reiterated
08/25/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Eli Lilly & Co (NYSE: LLY)
Bank of America Securities Analyst forecast on GB:0Q1G
Jason Gerberry
Bank of America Securities
Bank of America Securities
CHF1,087.06
Buy
6.57%
Upside
Reiterated
08/21/26
Eli Lilly Buy Rating Reiterated on Durable Incretin and Obesity Growth, Price Target Maintained at $1,344
Berenberg Bank Analyst forecast on GB:0Q1G
Kerry Holford
Berenberg Bank
Berenberg Bank
CHF918.02→CHF986.77
Hold
-3.26%
Downside
Reiterated
08/13/26
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY) and Ascendis Pharma (NASDAQ: ASND)
Truist Financial Analyst forecast on GB:0Q1G
Srikripa Devarakonda
Truist Financial
Truist Financial
CHF1,112.94
Buy
9.11%
Upside
Reiterated
08/11/26
Truist Financial Sticks to Their Buy Rating for Eli Lilly & Co (LLY)
Goldman Sachs Analyst forecast on GB:0Q1G
Asad Haider
Goldman Sachs
Goldman Sachs
CHF1,037.72→CHF1,105.66
Buy
8.40%
Upside
Reiterated
08/06/26
Analysts' Top Healthcare Picks: Amgen (AMGN), Eli Lilly & Co (LLY)
Morgan Stanley Analyst forecast on GB:0Q1G
Terence Flynn
Morgan Stanley
Morgan Stanley
CHF1,089.49→CHF1,147.72
Buy
12.52%
Upside
Reiterated
08/06/26
Eli Lilly price target raised to $1,419 from $1,347 at Morgan StanleyEli Lilly price target raised to $1,419 from $1,347 at Morgan Stanley
Scotiabank Analyst forecast on GB:0Q1G
Louise Chen
Scotiabank
Scotiabank
CHF1,051.47
Buy
3.09%
Upside
Reiterated
08/06/26
Scotiabank Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)
Cantor Fitzgerald Analyst forecast on GB:0Q1G
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
CHF1,091.91→CHF1,140.44
Buy
11.81%
Upside
Reiterated
08/06/26
Eli Lilly price target raised to $1,410 from $1,350 at Cantor FitzgeraldEli Lilly price target raised to $1,410 from $1,350 at Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
JAZZJazz Pharmaceuticals
AXGNAxoGen
ARDXArdelyx
ARWRArrowhead Pharmaceuticals
PTGXProtagonist Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eli Lilly & Co

3 Months
Louise ChenScotiabank
Success Rate
28/38 ratings generated profit
74%
Average Return
+8.84%
Copying Louise Chen's trades and holding each position for 3 Months would result in 73.68% of your transactions generating a profit, with an average return of +8.84% per trade.
1 Year
Geoff MeachamCiti
Success Rate
40/44 ratings generated profit
91%
Average Return
+41.20%
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +41.20% per trade.
2 Years
Steve ScalaTD Cowen
Success Rate
37/38 ratings generated profit
97%
Average Return
+51.02%
Copying Steve Scala's trades and holding each position for 2 Years would result in 97.37% of your transactions generating a profit, with an average return of +51.02% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0Q1G Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
5
3
2
0
0
Buy
85
84
76
70
53
Hold
2
3
3
4
3
Sell
2
0
0
0
1
Strong Sell
0
0
0
0
0
total
94
90
81
74
57
In the current month, 0Q1G has received 53 Buy Ratings, 3 Hold Ratings, and 1 Sell Ratings. 0Q1G average Analyst price target in the past 3 months is 1,110.18.
Each month's total comprises the sum of three months' worth of ratings.

0Q1G Financial Forecast

0Q1G Earnings Forecast

Next quarter’s earnings estimate for 0Q1G is CHF8.01 with a range of CHF7.28 to CHF9.19. The previous quarter’s EPS was CHF6.81. 0Q1G beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0Q1G has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0Q1G is CHF8.01 with a range of CHF7.28 to CHF9.19. The previous quarter’s EPS was CHF6.81. 0Q1G beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0Q1G has Performed in-line its overall industry.

0Q1G Sales Forecast

Next quarter’s sales forecast for 0Q1G is CHF18.02B with a range of CHF17.06B to CHF19.55B. The previous quarter’s sales results were CHF18.68B. 0Q1G beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0Q1G has Performed in-line its overall industry.
Next quarter’s sales forecast for 0Q1G is CHF18.02B with a range of CHF17.06B to CHF19.55B. The previous quarter’s sales results were CHF18.68B. 0Q1G beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0Q1G has Performed in-line its overall industry.

0Q1G Stock Forecast FAQ

What is GB:0Q1G’s average 12-month price target, according to analysts?
Based on analyst ratings, Eli Lilly & Co’s 12-month average price target is 1,110.18.
    What is GB:0Q1G’s upside potential, based on the analysts’ average price target?
    Eli Lilly & Co has 8.84% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Eli Lilly & Co a Buy, Sell or Hold?
          Eli Lilly & Co has a consensus rating of Strong Buy, which is based on 18 buy ratings, 2 hold ratings and 1 sell ratings.
            What is Eli Lilly & Co’s share price target?
            The average share price target for Eli Lilly & Co is 1,110.18. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is CHF1,294.12 ,and the lowest forecast is CHF760.30. The average share price target represents 8.84% Increase from the current price of CHF1,020.
              What do analysts say about Eli Lilly & Co?
              Eli Lilly & Co’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.
                How can I buy shares of Eli Lilly & Co?
                To buy shares of GB:0Q1G, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.